The Centers for Disease Control in the USA has changed, for the first time since 1961, the guidelines regarding administration of polio vaccine.
After two years of study, the CDC has recommended that children receive the polio vaccine in a combination of inactivated and oral formulations. Under this schedule, infants will be injected with the inactivated polio virus twice in their first four months, followed by two oral doses between one and six years of age. OPV is the only form which stimulates mucosal immunity. The polio virus is transmitted via the alimentary canal, so mucosal immunity is particularly important (Marketletter July 31, 1995).
CDC Urges Change To IPV Currently, most children receive four doses of oral vaccine by the age of two, but in June an advisory panel to the CDC urged the change because of eight to 10 polio cases in the USA every year in adults and children resulting from the oral vaccine, in which the virus is in a live but weakened form. The panel says that a switch to IPV should be made. This is a stronger version of the vaccine which causes only serum immunity, but does not prevent a carrier from infecting the unimmunized. The sequential schedule combining both IPV and OPV would therefore stimulate both serum and mucosal immunity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze